NPNeepa Patel

Neepa Patel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Neepa Patel has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Abhimanyu Mahajan

    James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders University of Cincinnati Cincinnati Ohio USA

    3 shared publications
  • Abdullah Alshammaa

    Department of Neurology, Henry Ford Hospital, 2799 W. Grand Boulevard, K-11 Detroit, MI 48202, USA

    1 shared publication
  • Achint Patel

    Department of Neurology, University of Arkansas Medical Center, Little Rock, AK, USA

    1 shared publication
  • Andrew Zillgitt

    Department of Neurology, Henry Ford Hospital, 2799 W. Grand Boulevard, K-11 Detroit, MI 48202, USA

    1 shared publication
  • Ayesha Ahmad

    Parkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA

    1 shared publication
  • Bisena Bulica

    Parkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA

    1 shared publication

Latest Publications

  • Open Access

    From medications to surgery: advances in the treatment of motor complications in Parkinson’s disease

    by Kanae Jennifer Nagao, Neepa J Patel

    Motor complications are responsible for the large burden of disability and poor quality of life in Parkinson's disease (PD). The pulsatile nature of stimulation with oral dopaminergic therapies due to relatively short pharmacokinetic profiles and dysfunctional gastrointestinal absorption have been attributed to the development of PD motor complications. In this review, we will provide an overview of the pharmacologic and surgical therapies currently available and under investigation for the treatment of motor fluctuations and dyskinesia.


  • Open Access

    Cervical Dystonia and Executive Function: A Pilot Magnetoencephalography Study

    by Abhimanyu Mahajan, Andrew Zillgitt, Abdullah Alshammaa, Neepa Patel, Christos Sidiropoulos, Peter A. LeWitt, Susan Bowyer

    Background: Cervical dystonia (CD) patients have impaired working memory, processing speed and visual-motor integration ability. We used magnetoencephalography (MEG) to investigate changes in cerebral oscillations in CD patients during an executive function test, before and after administration of botulinum toxin. Methods: MEG data were collected from five CD patients while they performed a visual continuous performance task (CPT), before and after they received a botulinum toxin injection. MEG data was also collected on five controls matched for age and gender. Coherence source imaging was performed to quantify network connectivity of subjects. Results: Controls demonstrated two errors with visual CPT; CD patients demonstrated six and three errors pre- and post-botulinum toxin respectively. After botulinum toxin, mean time from cue to correct response was 0.337 s in controls, 0.390 s in patients before botulinum toxin injection, and 0.366 s after the injection. Differences in coherence between controls and patients were found in the following brain regions: Fronto-frontal, fronto-parietal, fronto-striatal, fronto-occipital, parieto-parietal and temporo-parietal. Intrahemispheric and interhemispheric networks were affected. Post injection, there was minimal change in coherence in the above-mentioned networks. Discussion: Neuropsychological testing suggests difference in coherence in frontal circuits between CD cases and controls during the visual CPT, which may reflect subjects’ increased difficulty with the task. Botulinum toxin is associated with minimal improvement with executive function in CD.


  • Pimavanserin use in a movement disorders clinic: a single-center experience

    by Abhimanyu Mahajan, Bisena Bulica, Ayesha Ahmad, Patricia Kaminski, Peter LeWitt, Danette Taylor, Shana Krstevska, Neepa Patel

    Parkinson’s disease psychosis (PDP) is a disabling non-motor symptom of Parkinson’s disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening of Parkinsonism. Pimavanserin, a selective 5-HT2A receptor inverse agonist, was recently FDA-approved for treatment of PDP; however, there is limited information on its long-term use in PDP patients.


  • Cervical dystonia and substance abuse

    by For The Members Of The Dystonia Coalition, Abhimanyu Mahajan, Joseph Jankovic, Laura Marsh, Achint Patel, H. A. Jinnah, Cynthia Comella, Richard Barbano, Joel Perlmutter, Neepa Patel

    Objective To investigate the prevalence of substance abuse (SA) in patients with cervical dystonia (CD) and to correlate it with prevalence of psychiatric disorders. Methods Data on anxiety, depression, dystonia severity, and substance abuse were collected from ten sites participating in the Dystonia Coalition. Patients were divided into two groups according to the presence of SA, utilizing Structured Clinical Interview for DSM-4 criteria. Wilcoxon Rank-Sum test was used to analyze the difference in median scores on the questionnaires between the groups. Chi-square test was used to analyze association between opiate and benzodiazepine use and SA. Association between TWSTRS severity and SA and medication use was assessed. A two-tailed p value of < 0.05 was considered significant. SAS 9.3 (SAS Institute Inc., Cary, NC, USA) was used for all analyses. Results Of 208 CD patients, 23 (11%) were identified with SA; 26.3% of patients with SA were on opiates compared to 7.2% of CD patients without SA (p = 0.006). Compared to non-SA patients, those experiencing SA were more likely male (88.9%; p = 0.0007), younger (median age 55; p = 0.031), and scored worse on questionnaires assessing depression (p = 0.044, p = 0.005), anxiety (p = 0.003), and dystonia psychiatric severity (p = 0.033). The median TWSTRS motor severity scores were higher in SA patients compared to non-SA patients (20 versus 16, p = 0.0339). The median TWSTRS total disability, motor, and pain scores were higher in patients on opiates than patients who were not (12 versus 8, p = 0.0071; 18.5 versus 16, p = 0.0243; 12.4 versus 6.7, p = 0.0052, respectively). Conclusions Potential risk factors for SA in CD patients include younger age and male gender with comorbid anxiety, depression and other psychiatric problems. Caution should be exercised when prescribing drugs with potential for abuse in these patients.